Table 5. P-score for each treatment under the outcomes of overall survival and recurrence-free survival.
| Regimen | Overall survival | Recurrence-free survival | ||||
|---|---|---|---|---|---|---|
| 1y | 3y | 5y | 1y | 3y | 5y | |
| Ble + Cis + Ifo | 0.438 | 0.405 | 0.429 | 0.648 | 0.832 | - |
| Ble + Cis + MitoC + Vbl | 0.692 | 0.638 | 0.686 | - | - | - |
| Ble + Cis + Vbl | 0.529 | 0.274 | 0.259 | 0.556 | 0.428 | 0.429 |
| Ble + Cis + Vcr | 0.348 | 0.070 | 0.024 | 0.307 | 0.374 | 0.373 |
| Cis | 0.559 | 0.584 | 0.680 | 0.594 | 0.471 | 0.524 |
| Cis + Doc | 0.453 | 0.618 | 0.918 | 0.359 | 0.576 | 0.857 |
| Cis + Epi | 0.573 | 0.261 | 0.277 | 0.200 | 0.119 | 0.101 |
| Cis + Flu | 0.493 | 0.494 | 0.555 | 0.716 | 0.598 | 0.674 |
| Cis + Flu + Hyd | 0.670 | 0.768 | 0.834 | 0.623 | 0.688 | 0.801 |
| Cis + Ifo | 0.619 | 0.771 | - | 0.690 | 0.810 | - |
| Cis + Ifo + Pac | 0.582 | 0.856 | - | 0.612 | 0.799 | - |
| Cis + Methotrexate | 0.442 | 0.373 | 0.474 | 0.417 | 0.422 | 0.483 |
| Cis + Mitolactol | 0.438 | 0.685 | - | 0.466 | 0.118 | - |
| Cis + Pac | 0.389 | 0.791 | - | 0.550 | 0.706 | - |
| Cis + Topotecan | 0.423 | 0.593 | - | 0.483 | 0.686 | - |
| Cis + Vcr | 0.484 | 0.198 | 0.225 | 0.304 | 0.270 | 0.303 |
| Epi | 0.531 | 0.406 | 0.511 | 0.577 | 0.541 | 0.430 |
| Flu | 0.305 | 0.414 | 0.477 | 0.369 | 0.348 | 0.373 |
| Flu + MitoC | 0.463 | 0.750 | 0.767 | 0.495 | 0.632 | 0.641 |
| Hyd | 0.668 | 0.409 | 0.436 | 0.583 | 0.288 | 0.367 |
| MitoC | 0.563 | 0.664 | 0.700 | 0.653 | 0.820 | 0.940 |
| Nedaplatin + Pac | - | 0.264 | - | - | 0.264 | - |
| Placebo | 0.338 | 0.214 | 0.248 | 0.296 | 0.212 | 0.203 |